Triopsy Medical, Inc. announced it raised $250,000 in an initial filing from an offering of $500,000

Company

Location

About

Triopsy, a medical device company, has developed a comprehensive System ultimately intended to aid in the diagnosis and treatment planning of prostate cancer— the most commonly diagnosed significant male cancer and 2nd leading cause of cancer deaths. Created by two prostate cancer specialists, the Triopsy System is expected to achieve improvements in biopsy accuracy which may reduce the need for radical surgery or full radiation and lower costs for the healthcare industry.